Onderneming Biovica International AB (publ) Nasdaq Stockholm
Aandelen
SE0008613731
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
SEK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Blood-based Biomarker Assays
100,0
%
| 2 | 100,0 % | 3 | 100,0 % | +65,43% |
Verkoop per regio
SEK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
96,3
%
| 2 | 95,0 % | 3 | 96,3 % | +67,68% |
European Union excluding Sweden
3,7
%
| 0 | 5,0 % | 0 | 3,7 % | +22,55% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Anders Rylander
CEO | Chief Executive Officer | 54 | 01-01-10 |
Anders Morén
DFI | Director of Finance/CFO | 59 | 01-01-23 |
Hanna Ritzen
CTO | Chief Tech/Sci/R&D Officer | 45 | 01-01-22 |
Tomas Andersson
COO | Chief Operating Officer | 64 | 01-01-20 |
Joakim Arwidson
LAW | General Counsel | 56 | 01-01-21 |
Helle Fisker
SAM | Sales & Marketing | 55 | 01-01-21 |
Corporate Officer/Principal | 58 | 18-11-19 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 64 | 20-03-19 | |
Annika Berg
BRD | Director/Board Member | 61 | 01-01-20 |
Maria Holmlund
BRD | Director/Board Member | 68 | 01-01-16 |
Director/Board Member | 73 | 01-01-14 | |
Anders Rylander
CEO | Chief Executive Officer | 54 | 01-01-10 |
Director/Board Member | 58 | 01-01-13 | |
Henrik Osvald
BRD | Director/Board Member | 65 | 01-01-19 |
Director/Board Member | 59 | 01-01-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 6 271 293 | 0 | 0 | 92,54 % |
Aandeel B | 1 | 77 784 267 | 77 784 267 ( 100,00 %) | 0 |
Bedrijfsgegevens
Biovica International AB
Dag Hammarskjölds väg 54B Uppsala Science Park
752 37, Uppsala
+46 1 84 44 48 30
http://www.biovica.comSector
Verkoop per regio
Vaira. 1 jan. | Kapi. | |
---|---|---|
-42,89% | 8,21 mld. | |
+6,77% | 3,55 mld. | |
-1,35% | 2,24 mld. | |
-27,06% | 1,86 mld. | |
-21,23% | 1,68 mld. | |
+9,31% | 940 mln. | |
+29,42% | 751 mln. | |
-12,66% | 667 mln. | |
+1,19% | 286 mln. |